Doi, Toshihiko

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 1,784

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 892

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Maio, M., Ascierto, P. A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P. A., Bariani, G. M., De Jesus Acosta, A., Doi, T., Longo, F., et al. (2022) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 472

Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors

Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 362

Phase i study of single-agent utomilumab (PF-05082566), a 4-1bb/cd137 agonist, in patients with advanced cancer

Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., Cesari, R., Chen, Y., Davis, C. B., Huang, B., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 267

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

Harding, J. J., Moreno, V., Bang, Y.-J., Hong, M. H., Patnaik, A., Trigo, J., Szpurka, A. M., Yamamoto, N., Doi, T., Fu, S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 161

U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer

Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 90

690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

Patel, M. R., Doi, T., Koyama, T., Falchook, G. S., Friedman, C. F., Piha-Paul, S. A., Gutierrez, M., Awad, M. M., Mattour, A. H., Satoh, T., et al. (2023) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 33